Cryo-Cell market cap is $97.6 m, and annual revenue was $31.15 m in FY 2020

Cryo-Cell Gross profit (FY, 2020)21.5 M

Cryo-Cell Gross profit margin (FY, 2020), %69%

Cryo-Cell Net income (FY, 2020)3.6 M

Cryo-Cell EBIT (FY, 2020)7.7 M

Cryo-Cell Cash, 30-Nov-202010.4 M

Cryo-Cell EV94.4 M

Cryo-Cell revenue was $31.15 m in FY, 2020

Cryo-Cell revenue breakdown by business segment: 97.4% from Umbilical Cord Blood and Cord Tissue Stem Cell Service and 2.6% from Other

USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|

## Revenue | 23.1m | 25.4m | 29.2m | 31.8m | 31.1m |

| 10% | 10% | 15% | 9% | |

## Cost of goods sold | 5.8m | 6.7m | 8.5m | 10.0m | 9.7m |

## Gross profit | 17.4m | 18.7m | 20.7m | 21.8m | 21.5m |

| 75% | 74% | 71% | 68% | 69% |

## R&D expense | 53.1k | 41.2k | 91.8k | 30.1k | 23.9k |

## General and administrative expense | 14.7m | 13.5m | 15.6m | 14.9m | 14.3m |

## Operating expense total | 16.9m | 13.7m | 15.5m | 16.7m | 13.8m |

## Depreciation and amortization | 154.7k | 131.6k | 180.3k | 206.2k | 166.4k |

## EBIT | 433.6k | 5.0m | 5.2m | 5.1m | 7.7m |

| 2% | 20% | 18% | 16% | 25% |

## Interest expense | 947.3k | 1.3m | 1.5m | 1.7m | |

## Pre tax profit | (2.5m) | 3.6m | 3.6m | 3.4m | 5.0m |

## Income tax expense | (1.2m) | 1.3m | 4.5m | 1.1m | 1.4m |

## Net Income | (1.3m) | 2.3m | (854.8k) | 2.3m | 3.6m |

USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|

## Cash | 3.5m | 6.3m | 6.0m | 6.5m | 10.4m |

## Accounts Receivable | 4.1m | 5.1m | 5.9m | 6.1m | 6.3m |

## Prepaid Expenses | 395.5k | 372.2k | 461.8k | 500.3k | 611.6k |

## Inventories | 361.1k | 314.6k | 16.0m | 1.1m | 927.3k |

## Current Assets | 9.0m | 12.7m | 29.5m | 15.4m | 18.6m |

## PP&E | 979.5k | 882.4k | 1.5m | 1.8m | 1.6m |

## Goodwill | 1.9m | 1.9m | 1.9m | ||

## Total Assets | 19.5m | 23.9m | 42.4m | 42.9m | 46.2m |

## Accounts Payable | 1.5m | 1.9m | 1.3m | 1.4m | 957.4k |

## Short-term debt | 2.0m | 2.0m | 3.1m | 3.1m | 3.4m |

## Current Liabilities | 13.1m | 13.9m | 15.4m | 15.4m | 16.4m |

## Long-term debt | 7.8m | 5.3m | 9.8m | 7.3m | 3.7m |

## Total Debt | 9.8m | 7.3m | 12.9m | 10.4m | 7.1m |

## Total Liabilities | 35.0m | 36.4m | 51.3m | 49.8m | 48.9m |

## Common Stock | 125.0k | 129.0k | 136.0k | 136.0k | 136.3k |

## Preferred Stock | |||||

## Additional Paid-in Capital | 30.3m | 31.4m | 35.5m | 35.9m | 36.6m |

## Retained Earnings | (26.8m) | (24.5m) | (25.3m) | (22.4m) | (18.8m) |

## Total Equity | (15.4m) | (12.5m) | (8.9m) | (7.0m) | (2.7m) |

## Debt to Equity Ratio | -0.6 x | -0.6 x | -1.5 x | -1.5 x | |

## Debt to Assets Ratio | 0.5 x | 0.3 x | 0.3 x | 0.2 x | |

## Financial Leverage | -1.3 x | -1.9 x | -4.8 x | -6.2 x | -17.3 x |

USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|

## Net Income | (1.3m) | 2.3m | (854.8k) | 2.3m | 3.6m |

## Depreciation and Amortization | 286.7k | 230.0k | 317.3k | 401.3k | 372.3k |

## Accounts Receivable | (1.6m) | (1.1m) | (1.3m) | (997.1k) | (828.6k) |

## Inventories | 114.5k | 46.6k | 316.7k | (27.4k) | 454.9k |

## Accounts Payable | 329.6k | 443.1k | (666.9k) | 107.5k | (411.7k) |

## Cash From Operating Activities | 5.0m | 5.7m | 5.3m | 6.3m | 8.5m |

## Purchases of PP&E | (343.0k) | (98.3k) | (446.2k) | (662.3k) | (100.0k) |

## Cash From Investing Activities | (369.7k) | 93.0k | (11.3m) | (690.7k) | 357.5k |

## Short-term Borrowings | (3.1m) | ||||

## Long-term Borrowings | (1.5m) | (2.6m) | (3.3m) | (4.1m) | |

## Cash From Financing Activities | (5.3m) | (3.0m) | 5.7m | (5.1m) | (5.0m) |

## Net Change in Cash | (652.3k) | 2.8m | (239.1k) | 501.0k | 3.8m |

USD | FY, 2016 |
---|---|

## Revenue/Employee | 345.2k |

## Debt/Equity | -0.6 x |

## Debt/Assets | 0.5 x |

## Financial Leverage | -1.3 x |